Conference Coverage
Thrombectomy shows efficacy for basilar artery strokes
MONTREAL – A randomized trial got derailed by underrecruitment and crossovers, but still showed evidence of thrombectomy’s efficacy.
Conference Coverage
Large cohort study IDs prognostic factors in thromboangiitis obliterans
CHICAGO – Ethnicity and limb infection are independent predictors of poor outcomes, including limb amputation, in TAO.
From the Journals
AVERT: Apixaban reduced thromboembolism risk in cancer patients
Cancer patients treated with apixaban had a significantly lower rate of venous thromboembolism but a higher risk of major bleeds than did those...
Video
ARISTOPHANES: Apixaban edges other DOACS for octogenarians
CHICAGO – Insurance claims data from more than 50,000 U.S. octogenarians on a DOAC showed apixaban worked best and caused the fewest major bleeds...
Conference Coverage
CT opens extended window for stroke thrombolysis
MONTREAL – The new EXTEND findings “will have a major impact” on using an extended time window for thrombolysis in U.S. practice.
Conference Coverage
GARFIELD-AF registry: DOACs cut mortality 19%
MUNICH – Results from a worldwide registry with more than 26,000 atrial fibrillation patients showed better survival with a direct oral...
From the Journals
Atrial fib guidelines may fall short on oral anticoagulation
Oral anticoagulation threshold according to CHA2DS2-VASc score varied widely after accounting for varying stroke rates in published studies.
From the Journals
Expert panel updates guidelines on antithrombotic therapy for AF
The new guidelines highlight 60 key recommendations from the 12-person expert panel.
Conference Coverage
Synergy DES shines in acute MI
PARIS – Swedish registry report analyzes key clinical outcomes in more than 36,000 consecutive acute MI patients who received newer-generation...
Conference Coverage
How to identify DVT faster in pediatric osteomyelitis
MALMO, SWEDEN – Recognition of key risk factors warrants early screening ultrasound.
From the Journals
Obesity triples post-MI sudden cardiac death risk
The obesity paradox makes a showing in the risk of all-cause death.
From the Journals
New look at ATLAS suggests rivaroxaban may still have role in ACS
A reanalysis of the ATLAS ACS 2-TIMI 51 trial separated fatal and nonfatal events.
Conference Coverage
Amplatzer Amulet slashes stroke risk in A-fib
PARIS – “Given the high bleeding risk, single antiplatelet therapy seems to be a good option for these patients,” said Dr. Ulf Landmesser.
Conference Coverage
Design limitations may have compromised DVT intervention trial
WASHINGTON – The preferred evaluation – intravascular ultrasound – was not used.
News
First reversal agent for apixaban and rivaroxaban gets fast-track approval
Andexanet alfa approval puts factor Xa inhibitors in the same ballpark as dabigatran, reversible with idarucizumab.
Conference Coverage
Does warfarin cause acute kidney injury?
SAN DIEGO – Consider increased monitoring of renal function in certain patients.
From the Journals
Women’s representation in CV drug trials still lagging
We’ve come a long way in clinical trial representation of women, but there’s more work to do.
Conference Coverage
MI before age 50? Think familial hypercholesterolemia, substance abuse
More than one-third of patients with an MI before age 50 and an LDL cholesterol of at least 160 mg/dL meet criteria for FH.
Conference Coverage
Impaired kidney function no problem for dabigatran reversal
ORLANDO – Idarucizumab, reversal agent for the anticoagulant dabigatran, worked fine in patients with renal dysfunction.
